These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36506732)

  • 1. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
    Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
    Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Duloxetine on Oxaliplatin-induced Allodynia and Hyperalgesia in Rats.
    Wagner MA; Smith EML; Ayyash N; Toledo J; Rasheed Z; Holden JE
    Biol Res Nurs; 2024 Apr; 26(2):248-256. PubMed ID: 37902612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity.
    Yang L; Wang H; Lu W; Yang G; Lin Z; Chen R; Li H
    J Proteomics; 2022 Aug; 266():104682. PubMed ID: 35830924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.
    Yang Y; Zhao B; Gao X; Sun J; Ye J; Li J; Cao P
    J Exp Clin Cancer Res; 2021 Oct; 40(1):331. PubMed ID: 34686205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity.
    Yi Y; Li L; Song F; Li P; Chen M; Ni S; Zhang H; Zhou H; Zeng S; Jiang H
    Toxicology; 2021 Jul; 459():152853. PubMed ID: 34252480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.
    Lamoine S; Cumenal M; Barriere DA; Pereira V; Fereyrolles M; Prival L; Barbier J; Boudieu L; Brasset E; Bertin B; Renaud Y; Miot-Noirault E; Civiale MA; Balayssac D; Aissouni Y; Eschalier A; Busserolles J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.
    Huang KM; Leblanc AF; Uddin ME; Kim JY; Chen M; Eisenmann ED; Gibson AA; Li Y; Hong KW; DiGiacomo D; Xia SH; Alberti P; Chiorazzi A; Housley SN; Cope TC; Sprowl JA; Wang J; Loprinzi CL; Noonan A; Lustberg MB; Cavaletti G; Pabla N; Hu S; Sparreboom A
    J Clin Invest; 2020 Sep; 130(9):4601-4606. PubMed ID: 32484793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.
    Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Chang SC; Lan YT; Lin CC; Yen CC; Tzeng CH; Wang WS; Chiang HL; Teng CJ; Teng HW
    Support Care Cancer; 2012 Jul; 20(7):1491-7. PubMed ID: 21814779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
    Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
    J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy.
    Micov AM; Tomić MA; Todorović MB; Vuković MJ; Pecikoza UB; Jasnic NI; Djordjevic JD; Stepanović-Petrović RM
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Dec; 103():109975. PubMed ID: 32464241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
    Sprowl JA; Ciarimboli G; Lancaster CS; Giovinazzo H; Gibson AA; Du G; Janke LJ; Cavaletti G; Shields AF; Sparreboom A
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11199-204. PubMed ID: 23776246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function.
    Yang Y; Luo L; Cai X; Fang Y; Wang J; Chen G; Yang J; Zhou Q; Sun X; Cheng X; Yan H; Lu W; Hu C; Cao P
    Free Radic Biol Med; 2018 May; 120():13-24. PubMed ID: 29530794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin-induced Peripheral Neuropathy.
    Tsukushi Y; Kobuchi S; Ito Y; Sakaeda T
    Anticancer Res; 2024 Feb; 44(2):575-584. PubMed ID: 38307592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation.
    Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S
    Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.